811842-18-9 Usage
Uses
Used in Pharmaceutical Research:
2-AMINOMETHYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is used as a building block for the synthesis of various bioactive compounds, contributing to the development of new pharmaceutical agents.
Used in Medicinal Chemistry:
2-AMINOMETHYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is used as a potential drug candidate for the treatment of neurological and psychiatric disorders, due to its potential interaction with neurotransmitter receptors.
Used in Organic Synthesis:
2-AMINOMETHYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is used as an intermediate in the synthesis of other organic compounds, leveraging its structural and functional group properties.
Used in Controlled Environments:
2-AMINOMETHYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is used with caution in controlled environments to mitigate potential health hazards and environmental impact, emphasizing the importance of proper handling, storage, and usage protocols.
Check Digit Verification of cas no
The CAS Registry Mumber 811842-18-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,1,1,8,4 and 2 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 811842-18:
(8*8)+(7*1)+(6*1)+(5*8)+(4*4)+(3*2)+(2*1)+(1*8)=149
149 % 10 = 9
So 811842-18-9 is a valid CAS Registry Number.
InChI:InChI=1/C14H20N2O2/c15-10-13-8-4-5-9-16(13)14(17)18-11-12-6-2-1-3-7-12/h1-3,6-7,13H,4-5,8-11,15H2
811842-18-9Relevant articles and documents
Active agent prodrugs with heterocyclic linkers
-
Page/Page column 143; 144; 145, (2015/10/28)
The embodiments provide prodrug compounds of Formulae I-XVII. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XVII that provides controlled release of an active agent. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an active agent from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS
-
Page/Page column 112, (2009/06/27)
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinaldamage, skin senescence and UV-induced skin damage, and as chemo-or radiosensitizers for cancer treatment.
